
Repro Med Systems KRMD
$ 5.79
3.02%
Quarterly report 2025-Q3
added 11-12-2025
Repro Med Systems Deferred Revenue 2011-2026 | KRMD
Deferred revenue is the amount of money or obligations that a company has received in advance for goods or services that have not yet been delivered or performed. In other words, it is income that has already been received but has not yet been recognized in accounting as revenue because the goods or services have not yet been transferred to the customer.Features of the metric
- Sources of future cash inflows
A high level of deferred revenue indicates that the company has secured future cash flows, which positively affects forecasts of its financial condition and stability. - Assessment of operational stability
Deferred revenue reflects demand for the company’s products or services and its ability to attract customers willing to pay in advance. It is one of the indicators of business stability and its competitive advantages. - Risks and obligations
Although deferred revenue indicates future inflows, it also represents obligations that the company must fulfill. If fulfilling these obligations is delayed or impossible, it can negatively impact reputation and financial results. - Analysis of liquidity and cash flow
Inflows in the form of deferred revenue improve the company’s current liquidity since the funds are already in the accounts. However, investors need to assess the ratio of deferred revenue to fulfilled obligations to understand the actual financial capabilities and risks. - Impact on company valuation
In fundamental analysis, deferred revenue is taken into account for accurate revenue and profit forecasting, especially in industries with long-term contracts or subscriptions (e.g., IT sector, services, manufacturing).
Annual Deferred Revenue Repro Med Systems
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 125 K | - | 3.76 K | 22.5 K | 22.5 K | 22.5 K | 22.5 K | 22.5 K | - | 22.5 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 125 K | 3.76 K | 33 K |
Deferred Revenue of other stocks in the Medical instruments industry
| Issuer | Deferred Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Baxter International
BAX
|
131 M | $ 20.66 | 1.27 % | $ 10.5 B | ||
|
Luminex Corporation
LMNX
|
21.1 M | - | - | $ 1.75 B | ||
|
Akers Biosciences, Inc.
AKER
|
59.8 K | - | -9.52 % | $ 20.6 M | ||
|
Antares Pharma, Inc.
ATRS
|
3.94 M | - | - | $ 955 M | ||
|
Cantel Medical Corp.
CMD
|
26.2 M | - | -1.18 % | $ 3.4 B | ||
|
CRH Medical Corporation
CRHM
|
26.8 K | - | - | $ 282 M | ||
|
Hill-Rom Holdings, Inc.
HRC
|
110 M | - | -0.05 % | $ 10.3 B | ||
|
Ekso Bionics Holdings
EKSO
|
1.96 M | $ 8.15 | -7.6 % | $ 164 M | ||
|
Varian Medical Systems, Inc.
VAR
|
782 M | - | -0.02 % | $ 16.3 B | ||
|
Alcon
ALC
|
581 M | $ 80.67 | -0.38 % | $ 40.4 B | ||
|
Haemonetics Corporation
HAE
|
43.3 M | $ 84.98 | 2.36 % | $ 4.28 B | ||
|
AngioDynamics
ANGO
|
200 K | $ 10.02 | -8.29 % | $ 409 M | ||
|
Harvard Bioscience
HBIO
|
4.51 M | $ 0.66 | -1.92 % | $ 28 M | ||
|
The Cooper Companies
COO
|
128 M | $ 83.38 | -0.63 % | $ 16.6 B | ||
|
ICU Medical
ICUI
|
30.4 M | $ 152.88 | 1.7 % | $ 3.73 B | ||
|
iRhythm Technologies
IRTC
|
2.93 M | $ 188.16 | 0.41 % | $ 5.87 B | ||
|
LeMaitre Vascular
LMAT
|
552 K | $ 85.05 | 1.55 % | $ 1.91 B | ||
|
Masimo Corporation
MASI
|
95.5 M | $ 138.18 | 0.8 % | $ 7.36 B | ||
|
Intuitive Surgical
ISRG
|
469 M | $ 586.15 | -1.03 % | $ 208 B | ||
|
Merit Medical Systems
MMSI
|
572 K | $ 93.33 | 1.83 % | $ 5.43 B | ||
|
Microbot Medical
MBOT
|
16.8 K | $ 2.19 | 3.55 % | $ 22.3 M | ||
|
Nephros
NEPH
|
70 K | $ 5.07 | -1.74 % | $ 52.7 M | ||
|
Milestone Scientific
MLSS
|
340 K | $ 0.29 | 2.24 % | $ 23.1 M | ||
|
NeuroMetrix
NURO
|
1.96 M | - | 5.05 % | $ 9.02 M | ||
|
Envista Holdings Corporation
NVST
|
146 M | $ 23.52 | 2.53 % | $ 4.05 B | ||
|
OraSure Technologies
OSUR
|
3 M | $ 2.65 | 5.38 % | $ 197 M | ||
|
Pro-Dex
PDEX
|
202 K | $ 41.83 | 4.47 % | $ 138 M | ||
|
Predictive Oncology
POAI
|
305 K | $ 6.85 | 3.24 % | $ 37.4 M | ||
|
Pulse Biosciences
PLSE
|
16 K | $ 14.71 | -3.26 % | $ 707 M | ||
|
Repligen Corporation
RGEN
|
17.1 M | $ 165.12 | -2.32 % | $ 9.2 M | ||
|
ResMed
RMD
|
109 M | $ 250.85 | 1.07 % | $ 36.6 B | ||
|
BioLife Solutions
BLFS
|
103 K | $ 24.91 | -1.97 % | $ 1.15 B | ||
|
STERIS plc
STE
|
160 M | $ 260.64 | 0.52 % | $ 25.7 B | ||
|
Stereotaxis
STXS
|
6.66 M | $ 2.57 | -1.35 % | $ 207 M | ||
|
Retractable Technologies
RVP
|
377 K | $ 0.76 | -0.53 % | $ 22.8 M | ||
|
STAAR Surgical Company
STAA
|
3.75 M | $ 22.43 | 1.08 % | $ 1.1 B | ||
|
West Pharmaceutical Services
WST
|
49.6 M | $ 274.0 | -1.62 % | $ 20 B | ||
|
DENTSPLY SIRONA
XRAY
|
95 M | $ 12.53 | 1.25 % | $ 2.55 B |